Price (90d)
No price history yet — the daily price refresh runs once a day.
Signal Score (90d)
90Quote
Valuation & Ratios
Returns & Efficiency
Revenue & Net Income (Annual)
| Fiscal Year | Revenue | Net Income | EPS |
|---|---|---|---|
| 2026 | $65.6K | $-4.57M | $-0.04 |
| 2025 | $103.8K | $-4.29M | $-0.05 |
| 2024 | $170.2K | $-3.12M | $-0.04 |
| 2023 | $438.8K | $-2.61M | $-0.04 |
| 2022 | $267.1K | $-2.05M | $-0.03 |
Social Signal Score
Earnings
Mon, Aug 24(in 8 days)
Consensus estimate $-0.01 per share
- Thu, Jun 11$-0.01 vs $-0.01miss
- Thu, Nov 20$-0.01 vs $-0.01miss
- Wed, Aug 20$-0.01 vs $-0.01miss
- Wed, May 28$-0.01 vs $-0.01miss
- Wed, Feb 12$-0.01 vs $-0.01miss
- Thu, Nov 21$-0.01 vs $-0.01miss
Estimates and results for DGNOF via Financial Modeling Prep. Beating consensus says the company cleared the bar analysts set, not that the business grew.
Valuation
DGNOFhas no positive reported earnings per share, so an earnings-multiple projection can't be built for it. Companies are valued on other measures at this stage — revenue growth, cash burn, or book value — none of which this calculator models.
Mentions (1)
- Newsglobenewswire.com·2d ago·Negative
…ed Retinal Image Analysis to Saudi Arabia BROSSARD, Quebec, Aug. 13, 2026 (GLOBE NEWSWIRE) -- Diagnos Inc. (“DIAGNOS” or the “Corporation”) (TSX Venture: ADK, OTCQB: DGNOF, FWB: 4D4A), a Corporation dedicated to the early detection of eye-related health using Artificial Intelligence (AI) techniques, is pleased to announce that today, August 13, 2026, it has received Medical Device Marketing Authorization for the CARA System (CARA) from the Saudi Food and Drug Authority (SFDA). The version of CAR…
View source ↗